- At the 19th ISGE Congress, Mithra and Gedeon Richter presented the clinical results of Estelle® to an international scientific audience
- While Estetrol (E4) has recently been designated as a “New Active Substance” by the European Medicines Agency (EMA), doctors there have confirmed their strong interest in the use of E4 in contraception.
Liege, Belgium, 3 December, 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that physicians at the 19th Congress of the International Society of Gynecologic Endocrinology (ISGE) expressed a strong interest in the clinical results of Estelle®, Mithra’s novel combined oral contraceptive (COC) candidate.